Key result
CMV seropositivity is linked to ~170% higher odds of atherosclerotic disease in ESRD.
Why the study?
The contribution of cytomegalovirus seropositivity to the increased risk of cardiovascular disease in patients with end-stage renal disease was unclear.
Is CMV seropositivity associated with an increased prevalence of atherosclerotic disease in patients with end-stage renal disease?
Population
408 patients with end-stage renal disease evaluated for renal transplantation
Comparison
CMV seropositivity vs CMV seronegativity
Design
Retrospective observational study
Authors
Loading...
May identify higher atherosclerotic risk in ESRD; hypothesis-generating and should not yet change practice.
Observational (n=408)
Is CMV seropositivity associated with an increased prevalence of atherosclerotic disease in patients with end-stage renal disease?
Odds Ratio: 2.7
CMV seropositivity is independently associated with a higher prevalence of atherosclerotic disease in patients with end-stage renal disease, particularly when combined with elevated CRP.
Betjes et al. (2007) conducted an observational in End-stage renal disease (n=408). CMV seropositivity was evaluated on Positive medical history of atherosclerotic disease (OR 2.7). CMV seropositivity was independently associated with a positive medical history of atherosclerotic disease in patients with end-stage renal disease (OR 2.7).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: